Myeloma UK CEO to lead Prostate Cancer UK

Myeloma UK’s chief executive Laura Kerby is leaving to take the same role at Prostate Cancer UK.

Kerby leaves blood cancer charity Myeloma UK after 18 months and will take up her new post at Prostate Cancer UK in February 2022.

She joins the charity following her father’s experience with prostate cancer.

“My father is one of the 400,000 men in the UK living with a prostate cancer diagnosis, and I am determined to ensure future lives are neither shortened nor limited by the disease,” said Kerby.

“I passionately believe that working together, uniting the best science and clinical practice means that ultimately, we will be able to beat prostate cancer. It will be a privilege to bring my leadership experience and skills to help Prostate Cancer UK in this endeavour."

Prior to joining Myeloma UK she led Penny Brohn UK for six years and has also been managing director of consumer wellbeing at Nuffield Health.

Kerby replaces Angela Culhane, who is retiring after five years leading Prostate Cancer UK.

Prior to Kerby joining director of fundraising and supporter engagement Nicola Tallet will be acting chief executive.

Meet our new CEO. 👋

We’re thrilled to announce Laura Kerby as our new Chief Executive.

Laura will join us in February and will take up the baton from Angela Culhane, who is retiring this December after five successful years at the helm.

Read more: https://t.co/Byt0x58FiS pic.twitter.com/n5vIJYWdCN
— Prostate Cancer UK (@ProstateUK) December 3, 2021

Prostate Cancer UK chair Charles Packshaw added: “Laura’s extensive experience in both the charity world and the wider business world make her the ideal person to lead us forward as we work towards our vision of a future where lives are not limited by prostate cancer.”

Myeloma UK’s director of communications and brand has been appointed as acting chief executive while the charity appoints a permanent replacement for Kerby.

“The board felt it was important to appoint an acting chief executive from the current executive leadership team to ensure we maintained momentum behind the delivery of Myeloma UK’s long-term goals and plans,” said Myeloma UK chair Simon Linnett.

“Regarding the permanent appointment, the Board has already begun work on recruitment to ensure that the charity can move forward in the longer term with a CEO of the highest standard.”